Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Axitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 19/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 3/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 3/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 7/20 | 1.00 |
| ▸ | LCK | P06239 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | PAK4 | O96013 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | CSF1R | P07333 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | MET | P08581 | 2/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 2/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 2/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 2/20 | 1.00 |
| ▸ | TYK2 | P29597 | 2/20 | 1.00 |
| ▸ | AXL | P30530 | 2/20 | 1.00 |
| ▸ | BLK | P51451 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Axitinib SCHEMBL29384419 | 1.00 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL843204 | 1.00 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL29349703 | 1.00 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL29387511 | 1.00 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL172918 | 1.00 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL5248175 | 0.99 | KDR (0.98) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL5248178 | 0.99 | KDR (0.98) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL23044964 | 0.94 | KDR (0.88) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL29459456 | 0.94 | KDR (0.88) | KDRFGFR1FLT1FLT4LCK | |
| SCHEMBL24503457 | 0.91 | KDR (0.84) | KDRFGFR1FLT1FLT4LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140248347-A1 | PHARMACEUTICAL COMPOSITIONS OF N-METHYL-2-[3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL]-BENZAMIDE | PFIZER (US) | 2014-09-04 | — | — | US | disclosed |
| WO-2013046133-A1 | PHARMACEUTICAL COMPOSITIONS OF N-METHYL-2-[3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL]-BENZAMIDE | PFIZER INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| EP-2163544-A1 | Methods of preparing indazole compounds | Pfizer, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-2163544-A1 | Methods of preparing indazole compounds | Pfizer, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20070203196-A1 | METHODS OF PREPARING INDAZOLE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203196-A1 | METHODS OF PREPARING INDAZOLE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203196-A1 | METHODS OF PREPARING INDAZOLE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| EP-1809625-A1 | METHODS FOR PREPARING INDAZOLE COMPOUNDS | Pfizer, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1809621-A1 | METHODS OF PREPARING INDAZOLE COMPOUNDS | Pfizer, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-7232910-B2 | Methods of preparing indazole compounds | AGOURON PHARMACEUTICALS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232910-B2 | Methods of preparing indazole compounds | AGOURON PHARMACEUTICALS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232910-B2 | Methods of preparing indazole compounds | AGOURON PHARMACEUTICALS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| WO-2006048745-A1 | METHODS FOR PREPARING INDAZOLE COMPOUNDS | PFIZER INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006048744-A1 | METHODS OF PREPARING INDAZOLE COMPOUNDS | PFIZER INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060094881-A1 | Methods of preparing indazole compounds | AGOURON PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094881-A1 | Methods of preparing indazole compounds | CDK1, CDK2, CCNI | KDR 4124/4885FLT1 3066/4885FLT4 3300/4885 |
| US-20070203196-A1 | METHODS OF PREPARING INDAZOLE COMPOUNDS | CDK1, CDK2, CCNI | KDR 4124/4885FLT1 3066/4885FLT4 3300/4885 |
| US-20140248347-A1 | PHARMACEUTICAL COMPOSITIONS OF N-METHYL-2-[3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL]-BENZAMIDE | AXIN2, AURKA, AURKB | KDR 122/4885FLT1 369/4885FLT4 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.